Clinicians debate whether combining other drugs with osimertinib adds anything but toxicity to the care of patients with EGFR-mutated NSCLC.
Two physicians weigh the pros and cons of monotherapy over combination therapy for non–small cell lung cancer.
Allotments for this chemotherapy drug are waning but patients are willing to travel for treatment.
From the Journals
There has been an overall decline of 32% in cancer deaths as of 2019.
More intensive, repeated, and wide-reaching outreach efforts may be necessary to encourage more high-risk men and women to undergo lung cancer...
Several targeted NSCLC therapies are strongly associated with cardiac adverse events, such as conduction disease, QT prolongation, and heart...
Tepotinib for NSCLC, enfortumab vedotin for urothelial cancer and voxelotor for sickle cell disease are currently approved in the U.S.
Few eligible patients undergo CT screening despite survival benefits.
Obesity status over time may be more relevant to cancer risk than one-off measures.
CHEST gives 18 recommendations and further evidence of the benefits of CT screening.